MorphoSys

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

Retrieved on: 
星期四, 九月 15, 2022
Safety, Upjohn, RNA interference, Alnylam Pharmaceuticals, Patient, Chicago (franchise), U.S. Securities and Exchange Commission, Therapeutic index, Leadership, NASDAQ, Research, International law, Atlas Venture, Time, Cytokine, COVID-19, Orbital, Investment, Johnson & Johnson, Biochemistry, Tumor microenvironment, SEC, Takeda Oncology, Patent, Molecular biology, J&J, Atlas, Master of Laws, Agios Pharmaceuticals, Goal, Janssen, GLOBE, Biotechnology Innovation Organization, Immune system, Biogen, GPS, Therapy, Twitter, University of Antwerp, LinkedIn, Private Securities Litigation Reform Act, Cancer, Ortho Pharmaceutical, RNA, Biotechnology, R, University, Pharmaceutical industry, Management, ZymoGenetics, MorphoSys

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the companys board of directors.

Key Points: 
  • WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the companys board of directors.
  • The collective experience of Tom and John will be highly valuable as Xilio continues to advance its innovative scientific platform and promising pipeline of tumor-selective immunotherapy programs, said Paul Clancy, chair of the board of directors of Xilio Therapeutics.
  • Mr. Heyman currently serves as a member of the boards of directors of Legend Biotech, Akero Therapeutics, OptiNose, and Adagio Therapeutics.
  • He is chair of the board of directors of Hemab Therapeutics and the chairman and co-founder of Orbital Therapeutics.

SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer

Retrieved on: 
星期三, 九月 14, 2022
Constellation, Molecule, Doctor of Philosophy, Bachelor of Science in Human Biology, Knowledge, PPF (company), Acquisition, MorphoSys, University of Arizona, Biozentrum University of Basel, University of Edinburgh Business School, Patient, Head, Cancer, Edinburgh Business School, MBA, Leadership, Drug development, Northern Arizona University, Stanford University, Research, Biotechnology, GLOBE, University, Hoffmann-La Roche, Lead, Discovery, Pharmaceutical industry, Science, Biochemistry

PRAGUE, Czech Republic, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech , a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer.

Key Points: 
  • PRAGUE, Czech Republic, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech , a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer.
  • Martin Steegmaier brings over 20 years of experience in oncology drug discovery, drug development and business development.
  • His extensive knowledge of the biotech industry and clinical immuno-oncology will be crucial as SOTIO continues to advance multiple assets through the clinic.
  • As a seasoned biotechnology industry veteran and oncology drug discovery and development expert, Dr. Steegmaier will be an invaluable member of SOTIOs leadership team as we work to develop new, innovative treatments for cancer patients, said Radek Spisek, chief executive officer of SOTIO.

Leukemia Therapeutics Global Market Report 2022: A $20+ Billion Market in 2026 - Long-term Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
星期一, 九月 12, 2022
Pharmaceutical, Health, Oncology, GlaxoSmithKline, Therapy, Chronic lymphocytic leukemia, Immunotherapy, Lupin Limited, Texas Homecare, Prevalence, Exelixis, Asia-Pacific, Takeda Pharmaceutical Company, Organization, Acquisition, National, Growth, Leukemia, MorphoSys, Industry, Patient, Cancer, Acute leukemia, Bone marrow, Acute myeloid leukemia, Amgen, Pfizer, Bristol Myers Squibb, AbbVie, Celgene, Lymphatic system, Immune system, Hospital, National Cancer Institute, Medical device, Pharmaceutical industry, Oil, Trillium

The leukemia therapeutics market consists of sales of the leukemia therapeutics by entities (organizations, sole traders, and partnerships) that are used for the treatment of leukemia.

Key Points: 
  • The leukemia therapeutics market consists of sales of the leukemia therapeutics by entities (organizations, sole traders, and partnerships) that are used for the treatment of leukemia.
  • The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The leukemia therapeutics market research report is one of a series of new reports that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry.
  • Global Leukemia Therapeutics Market, Segmentation By Type Of Leukemia, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division

Retrieved on: 
星期一, 九月 12, 2022
Bayer, Engineering, Daniel, CHF, CORE, Senior, Growth, Gene, CEO, Cell, Technical University of Berlin, Institute of technology, Biopharmaceutical, DE, Novartis, Board of directors, Leadership, Process, Board, Lonza Group, Executive Committee, AI, Fine chemical, Management, MorphoSys, Chemistry

Daniel takes over the role from Jean-Christophe Hyvert, who continues to serve as President of Lonzas Biologics Division.

Key Points: 
  • Daniel takes over the role from Jean-Christophe Hyvert, who continues to serve as President of Lonzas Biologics Division.
  • Daniel joins Lonza Group with more than two decades of experience in the pharmaceutical industry, including senior positions at Novartis and Bayer Healthcare.
  • Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division.
  • Albert M. Baehny, Chairman, Lonza, commented: We extend a warm welcome to Daniel as he joins the Lonza Group Executive Committee and takes on the leadership of Cell & Gene.

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

Retrieved on: 
星期五, 九月 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, European Medicines Agency, EMA, CEO, Cancer, Registry, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DLBCL, National Medical Products Administration, Mental Health Commission of Canada, Hematology, ASCT, ADCC, Tafasitamab, Disclosure, Food, NMPA, Lymphoma, Lymphoid leukemia, FC, HKEX, MorphoSys, FDA, Immunotherapy, Incyte, Adult, CD19, Knowledge, Lenalidomide, Apoptosis, ADCP, Patient, Pharmaceutical industry, Health insurance, Vaccine

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, DLBCL is the most common type of non-Hodgkin lymphoma1.

Key Points: 
  • Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, DLBCL is the most common type of non-Hodgkin lymphoma1.
  • We will accelerate the clinical development of registrational trial of tafasitamab in combination with lenalidomide to help address the unmet needs of eligible DLBCL patients in China.
  • As part of this early access program, the first prescription of tafasitamab in combination with lenalidomide was filed in July at the Ruijin Hainan Hospital for an eligible DLBCL patient.
  • Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Retrieved on: 
星期三, 八月 31, 2022
FDA, Health, Stem Cells, Other Health, General Health, Pharmaceutical, European Medicines Agency, EMA, BLA, CEO, Cancer, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DLBCL, National Medical Products Administration, Mental Health Commission of Canada, Hematology, ASCT, ADCC, Tafasitamab, Disclosure, Food, Department, NMPA, Lymphoma, Lymphoid leukemia, FC, HKEX, MorphoSys, FDA, Immunotherapy, New Jersey Department of Health, Incyte, Adult, CD19, Knowledge, Lenalidomide, Apoptosis, ADCP, Patient, Pharmaceutical industry, Vaccine

Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in combination with lenalidomide for the treatment of relapsed or refractory DLBCL patients who are not eligible for ASCT.

Key Points: 
  • Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in combination with lenalidomide for the treatment of relapsed or refractory DLBCL patients who are not eligible for ASCT.
  • Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.
  • We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide.
  • Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

Retrieved on: 
星期三, 八月 3, 2022
Annual report, Investor, ASCT, U.S. Securities and Exchange Commission, Apoptosis, Lenalidomide, Risk, BST, Patient, Food, CEST, Communication, IFRS, Judgement, Industry, LinkedIn, CD19, Tafasitamab, Adult, ADCC, Regulation of tobacco by the U.S. Food and Drug Administration, Lymphoid leukemia, Cancer, DLBCL, Incyte, Twitter, ADCP, Webcast, FC, Immunotherapy, Clinical trial, Vaccine, Pharmaceutical industry, MorphoSys

*Value as of December 31, 2021

Key Points: 
  • *Value as of December 31, 2021
    MorphoSys will hold its conference call and webcast on August 4, 2022, to present the results of the second quarter and first half of 2022 and the outlook for 2022.
  • The statement for the second quarter/first half year of 2022 (IFRS) are available for download at: https://www.morphosys.com/en/investors/financial-information
    At MorphoSys, we are driven by our mission: More life for people with cancer.
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.
  • MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.

MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

Retrieved on: 
星期三, 八月 3, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Annual report, Investor, ASCT, U.S. Securities and Exchange Commission, Apoptosis, Lenalidomide, Risk, BST, Patient, Food, CEST, Communication, IFRS, Judgement, Industry, LinkedIn, CD19, Tafasitamab, Adult, ADCC, Regulation of tobacco by the U.S. Food and Drug Administration, Lymphoid leukemia, Cancer, DLBCL, Incyte, Twitter, ADCP, Webcast, FC, Immunotherapy, Clinical trial, Vaccine, Pharmaceutical industry, MorphoSys

*Value as of December 31, 2021

Key Points: 
  • *Value as of December 31, 2021
    MorphoSys will hold its conference call and webcast on August 4, 2022, to present the results of the second quarter and first half of 2022 and the outlook for 2022.
  • The statement for the second quarter/first half year of 2022 (IFRS) are available for download at: https://www.morphosys.com/en/investors/financial-information
    At MorphoSys, we are driven by our mission: More life for people with cancer.
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.
  • MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.

DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022

Retrieved on: 
星期四, 七月 28, 2022
BST, Industry, Twitter, U.S. Securities and Exchange Commission, Judgement, NASDAQ, Conference, Cancer, EDT, Webcast, Q&A, Clinical trial, Management, LinkedIn, Patient, Annual report, Communication, Risk, CEST, Investor, FSE, Video game, Flour, Risk management, MorphoSys

Invitation to MorphoSys Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022

Key Points: 
  • Invitation to MorphoSys Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00 pm EDT).
  • MorphoSys' Management team will host a conference call and webcast on August 4, 2022 at 2:00 pm CEST (1:00 pm BST; 8:00 am EDT) to present the second quarter and first half year financial results 2022 and provide an outlook for 2022.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.
  • Dial-in number for the conference call (2:00 pm CEST; 1:00 pm BST; 8:00 am EDT):
    Please dial in 10 minutes before the beginning of the conference.

DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

Retrieved on: 
星期二, 七月 26, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, FC, Industry, Twitter, Food, SG, U.S. Securities and Exchange Commission, Tafasitamab, Lenalidomide, Apoptosis, Judgement, Income, Adult, Lymphoid leukemia, DLBCL, Cancer, Clinical trial, ADCC, Immunotherapy, Patient, LinkedIn, Annual report, CD19, Communication, ADCP, Risk, ASCT, Bookkeeping, Health insurance, Vaccine, Pharmaceutical industry, MorphoSys, Incyte

100% of Monjuvi U.S. product sales are recorded on MorphoSys income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.

Key Points: 
  • 100% of Monjuvi U.S. product sales are recorded on MorphoSys income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
  • Gross Margin for Monjuvi U.S. Net Product Sales
    100% of Monjuvi U.S. product cost of sales are recorded on MorphoSys income statement and related profit/loss is split 50/50 between MorphoSys and Incyte.
  • 53% to 58% of mid-point of SG&A expenses represent Monjuvi U.S. selling costs of which 100% are recorded in MorphoSys income statement.
  • Full results will be published on August 3, 2022, followed by a conference call on August 4, 2022.